Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Yoshihara

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Haematologica|April 17, 2025
Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison studyTakeshi Yoroidaka, Hiroyuki Takamatsu, Ryota Urushihara, et al.
British Journal of Haematology|April 15, 2026
Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphomaYasuyuki Arai, Tomoyasu Jo, Takayuki Sato, et al.
British Journal of Haematology|April 28, 2026
Impact of CD34<sup>+</sup> cell dose on outcomes of related allogeneic PBSCT in adult AML patientsYusuke Toda, Tomoyasu Jo, Yasuyuki Arai, et al.
American Journal of Hematology|May 23, 2025
Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First TransplantationKazuki Yoshimura, Hideki Nakasone, Masaharu Tamaki, et al.
Bone Marrow Transplantation|June 9, 2025
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemiaMasahiro Teramoto, Yoshimitsu Shimomura, Hiroki Hosoi, et al.
Blood Advances|April 22, 2026
Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry AnalysisYu Yagi, Yusuke Kanemasa, Toshiki Terao, et al.
Annals of Hematology|August 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patientsYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, et al.
Microbiology and Immunology|March 20, 2004
WT1 peptide-based immunotherapy for patients with lung cancer: report of two casesAkihiro Tsuboi, Yoshihiro Oka, Tadashi Osaki, et al.
BMJ Open|July 11, 2019
Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trialKenichi Yamahara, Akiko Hamada, Toshihiro Soma, et al.
Hematology (Amsterdam, Netherlands)|April 29, 2025
Insights into very elderly multiple myeloma treatment from Kansai Myeloma ForumYusuke Okayama, Teruhito Takakuwa, Yuji Shimura, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Haematologica|April 17, 2025
Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison studyTakeshi Yoroidaka, Hiroyuki Takamatsu, Ryota Urushihara, et al.
British Journal of Haematology|April 15, 2026
Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphomaYasuyuki Arai, Tomoyasu Jo, Takayuki Sato, et al.
British Journal of Haematology|April 28, 2026
Impact of CD34<sup>+</sup> cell dose on outcomes of related allogeneic PBSCT in adult AML patientsYusuke Toda, Tomoyasu Jo, Yasuyuki Arai, et al.
American Journal of Hematology|May 23, 2025
Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First TransplantationKazuki Yoshimura, Hideki Nakasone, Masaharu Tamaki, et al.
Bone Marrow Transplantation|June 9, 2025
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemiaMasahiro Teramoto, Yoshimitsu Shimomura, Hiroki Hosoi, et al.
Blood Advances|April 22, 2026
Drivers of Temporal Improvement in CAR T-Cell Therapy for Large B-Cell Lymphoma: A Japanese Nationwide Registry AnalysisYu Yagi, Yusuke Kanemasa, Toshiki Terao, et al.
Annals of Hematology|August 21, 2024
The impact of renal function on initial therapy in transplant-ineligible multiple myeloma patientsYutaka Shimazu, Junya Kanda, Teruhito Takakuwa, et al.
Microbiology and Immunology|March 20, 2004
WT1 peptide-based immunotherapy for patients with lung cancer: report of two casesAkihiro Tsuboi, Yoshihiro Oka, Tadashi Osaki, et al.
BMJ Open|July 11, 2019
Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trialKenichi Yamahara, Akiko Hamada, Toshihiro Soma, et al.
Hematology (Amsterdam, Netherlands)|April 29, 2025
Insights into very elderly multiple myeloma treatment from Kansai Myeloma ForumYusuke Okayama, Teruhito Takakuwa, Yuji Shimura, et al.
Pageof 15